Introduction {#s1}
============

Small vessel disease (SVD) of the brain is a leading cause of stroke and age-related cognitive decline and disability for which there are currently no treatments ([@bib36]). Our limited understanding of the pathogenesis of cerebral SVD is a major obstacle to the development of treatments. Monogenic forms of these diseases, such as CADASIL (Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy), provide a window into the mechanism underlying much more common, but largely indistinguishable, sporadic forms of SVD ([@bib24]). CADASIL, the most common hereditary cerebral SVD, is caused by dominant mutations in the NOTCH3 receptor that stereotypically lead to the extracellular deposition of NOTCH3 ectodomain (Notch3^ECD^) and aggregates of other proteins on vessels ([@bib22]; [@bib8]; [@bib33]). A deficit in cerebral blood flow (CBF) hemodynamics is an early feature of the disease, suggesting that cerebrovascular dysfunction may have a key role in disease pathogenesis ([@bib7]; [@bib39]; [@bib30]).

Small vessels of the brain have unique functional properties that ensure that the brain, which has a limited capacity to store energy, maintains an adequate supply of blood-borne nutrients in the face of variations in blood pressure and changing neuronal energy demands. Cerebral arteries exist in a partially constricted state called \'myogenic tone\', which reflects an intrinsic contractile response of arterial myocytes to increases in intravascular pressure. Thus, these arteries are positioned to dilate, and thereby increase local CBF, in response to elevated neuronal activity. This phenomenon, known as functional hyperemia, serves to satisfy enhanced glucose and oxygen demands of active neurons ([@bib18]). Impaired functional hyperemia and CBF autoregulation, attenuated CBF responses to topical application of vasodilators, and diminished myogenic responses of cerebral arteries and arterioles are early and prominent features of the well-established *TgNotch3^R169C^* CADASIL mouse model ([@bib23]; [@bib12]; [@bib6]). The mechanisms underlying this cerebrovascular dysfunction are poorly understood.

Recently, we found that TIMP3 (tissue inhibitor of metalloproteinases-3) forms complexes with Notch3^ECD^ and abnormally accumulates in the extracellular matrix of brain vessels of patients and mice with CADASIL ([@bib33]). Remarkably, genetic overexpression of TIMP3 recapitulates both CBF and myogenic-response deficits of the CADASIL model; conversely, genetic reduction of TIMP3 in CADASIL model mice restores normal function ([@bib6]). TIMP family members are key regulators of the metalloproteinases that degrade the extracellular matrix. Within the TIMP family, TIMP3 has the broadest spectrum of substrates, which extends to members of the ADAM (a disintegrin and metalloproteinases) family. These metalloproteinases proteolytically release the extracellular domains of membrane-bound cytokines, cell adhesion molecules and growth factors, such as tumor necrosis factor-α and several ligands of the epidermal growth factor receptor (EGFR) family, including HB-EGF (heparin-binding EGF-like growth factor) ([@bib4]; [@bib26]; [@bib2]). As such, in addition to being a powerful regulator of extracellular matrix remodeling in various organs ([@bib2]), TIMP3 is a key player in inflammatory pathologies and autoimmune diseases through regulation of cell surface proteins ([@bib4]; [@bib26]). However, how metalloproteinase inhibition might dynamically regulate arterial tone and CBF hemodynamics is unclear.

In another recent study, we established that upregulation of voltage-gated potassium (K~V~) channels at the plasma membrane of arterial myocytes is responsible for the diminished myogenic responses of cerebral arteries and penetrating arterioles in the *TgNotch3^R169C^* CADASIL model. Notably, an influence of the endothelium in myogenic tone deficit was ruled out ([@bib12]). K~V~ channels play an important and dynamic role in opposing pressure-induced depolarization and vasoconstriction ([@bib31]). Furthermore, we ([@bib12]) and our collaborators ([@bib28]) have found that down-regulation of plasma membrane K~V~ channels through activation of the EGFR pathway restores normal responses to pressure. Collectively, our results suggest a fundamental linkage between the activity of TIMP3 in the extracellular matrix of cerebral arterial myocytes and cerebral arterial tone.

Here, we find that the ADAM17/HB-EGF/EGFR (ErbB1/ErbB4) signaling axis is a key TIMP3-sensitive signaling module that regulates CBF responses and the myogenic tone of cerebral arteries. We further provide evidence that disruption of this TIMP3-sensitive pathway mediates cerebrovascular dysfunction in the *TgNotch3^R169C^ *CADASIL model and identify upregulated K~V~ channel current density in cerebral arterial myocytes as a heretofore-unrecognized effector of this pathway. These insights into the relationship between TIMP3 activity and cerebral arterial tone may ultimately lead to therapeutic options in cerebral SVD.

Results {#s2}
=======

Exogenous TIMP3, but neither TIMP1 nor TIMP2, strongly attenuates CBF responses {#s2-1}
-------------------------------------------------------------------------------

To explore the role of TIMP3 in the regulation of CBF, we monitored CBF responses in wild-type mice equipped with an open cranial window over the somatosensory cortex, before and after the application of recombinant TIMP3 as well as TIMP1 or TIMP2 ([Figure 1A](#fig1){ref-type="fig"}; [Figure 1---source data 1](#SD1-data){ref-type="supplementary-material"}). We initially ensured that a recombinant protein applied over the cranial window could enter the brain. In the absence of robust anti-TIMP3 antibody suitable for immunohistochemistry and of an in situ assay to detect TIMP3 activity, we assessed brain penetration of Fluorescein isothiocyanate-labeled albumin (FITC-BSA, 66 kDa). After 30 min of continuous superfusion, fluorescence imaging of fixed vibratome slices showed that FITC-BSA entered the cortex along penetrating arteries beneath the cranial window ([Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}), consistent with transport via the glymphatic system ([@bib19]). We found that TIMP3 (40 nM) did not affect resting CBF ([Figure 1B](#fig1){ref-type="fig"}), but did strongly reduce the increase in CBF evoked by whisker stimulation ([Figure 1C,D](#fig1){ref-type="fig"}; [Figure 1---source data 2](#SD2-data){ref-type="supplementary-material"},[3](#SD3-data){ref-type="supplementary-material"}). Superfusion of 8 nM TIMP3 similarly attenuated functional hyperemia ([Figure 1---figure supplement 2](#fig1s2){ref-type="fig"}; [Figure 1---source data 2](#SD2-data){ref-type="supplementary-material"},[3](#SD3-data){ref-type="supplementary-material"}). To rule out a possible effect of TIMP3 on neural activity, we recorded evoked neural activity during TIMP3 application ([Figure 1E](#fig1){ref-type="fig"}). We found that the amplitude of the somatosensory fields potentials produced by electrical stimulation of the whisker pad was unaltered by TIMP3 superfusion ([Figure 1F](#fig1){ref-type="fig"}).10.7554/eLife.17536.003Figure 1.Exogenous TIMP3 specifically impairs cerebrovascular reactivity.(**A**) Schematic representation of the experimental protocol used to test the effects of recombinant TIMP1 (50 nM), TIMP2 (50 nM) or TIMP3 (40 nM) superfusion on the somatosensory cortex of 2-month-old wild-type mice. (**B**--**D**) Resting CBF (**B**) and CBF responses to whisker stimulation (**C**, **D**) were evaluated upon superfusion of vehicle or TIMP proteins. (**C**) Representative trace of CBF responses to whisker stimulation upon superfusion of vehicle or TIMP proteins (**C**). (**E**) Representative trace of the field potentials evoked by whisker stimulation upon vehicle or TIMP3 superfusion, showing typical sharp positive (P1)-negative (N1) waves followed by a slower positive-negative waveform occurring within 80 ms post stimulus ([@bib13]). (**F**) The amplitude of the negative wave (N1, asterisk in **E**) of the field potential was not affected by TIMP3 superfusion (p=0.79). (**G**, **H**) CBF responses to topical application of adenosine (**G**) or acetylcholine (**H**) upon superfusion of vehicle or TIMP proteins. Significance was determined by one-way ANOVA followed by Tukey's post-hoc test (**B**, **D**, **G**, **H**) or unpaired Student's t-test (**F**). (\*p\<0.05, \*\*\*p\<0.001 compared to vehicle; n = 5 mice/groups). Error bars indicate SEM.**DOI:** [http://dx.doi.org/10.7554/eLife.17536.003](10.7554/eLife.17536.003)10.7554/eLife.17536.004Figure 1---source data 1.Reagents used for [Figure 1](#fig1){ref-type="fig"}.**DOI:** [http://dx.doi.org/10.7554/eLife.17536.004](10.7554/eLife.17536.004)10.7554/eLife.17536.005Figure 1---source data 2.Main physiological variables of mice studied in [Figure 1](#fig1){ref-type="fig"}.**DOI:** [http://dx.doi.org/10.7554/eLife.17536.005](10.7554/eLife.17536.005)10.7554/eLife.17536.006Figure 1---source data 3.Numerical data that were used to generate the bar charts in [Figure 1](#fig1){ref-type="fig"}.**DOI:** [http://dx.doi.org/10.7554/eLife.17536.006](10.7554/eLife.17536.006)10.7554/eLife.17536.007Figure 1---figure supplement 1.Assessment of brain penetration of fluorescein isothiocyanate labelled serum albumin (FITC-BSA) superfused over the cranial window.(**A**) FITC-BSA was topically superfused over the somatosensory cortex for 30 min, the brain was removed at the time of killing, post-fixed, sectioned in 50-µm-thick coronal slices through the perfusion site using a vibratome and immunostained with anti-smooth muscle alpha actin conjugated to Alexa 594 (a-SMA). Shown is a representative vibratome coronal section counterstained with DAPI and examined by epifluorescence microscopy (merge of DAPI and FITC images). The pia matter as well the penetrating vessels under the window (left side) display spontaneous FITC fluorescence. (**B**--**D**) Higher magnification of selected regions ipsilateral to the window (1-B, 2-C) or contralateral to the window (3-D), delineated in **A**, showing that FITC-BSA entered the cortex along the penetrating arteries (white arrowheads) beneath the cranial window (**B**, **C**). Scale bar represents 500 µm (**A**) and 100 µm (**B**--**D**).**DOI:** [http://dx.doi.org/10.7554/eLife.17536.007](10.7554/eLife.17536.007)10.7554/eLife.17536.008Figure 1---figure supplement 2.Exogenous TIMP3 (8 nM) impairs cerebrovascular reactivity.(**A**--**D**) Resting CBF (**A**) and CBF responses to whisker stimulation (**B**) or topical application of acetylcholine (**C**) or adenosine (**D**) were evaluated upon superfusion of TIMP3 (8 nM) or vehicle. Significance was determined by one-way ANOVA followed by Tukey's post-hoc test. (\*\*\*p\<0.001 compared with vehicle; n = 5 mice/group).**DOI:** [http://dx.doi.org/10.7554/eLife.17536.008](10.7554/eLife.17536.008)

The known TIMPs share 38--49% amino acid identity and inhibit most matrix metalloproteinases (MMPs). However, differences in substrate selectivity and inhibitory properties between different TIMPs have been described ([@bib26]; [@bib44]) ([Figure 1---source data 1](#SD1-data){ref-type="supplementary-material"}). This prompted us to assess the effects of other TIMPs on functional hyperemia. In sharp contrast to TIMP3, neither exogenous TIMP1 (50 nM) nor TIMP2 (50 nM) altered functional hyperemia ([Figure 1C,D](#fig1){ref-type="fig"}; [Figure 1---source data 2](#SD2-data){ref-type="supplementary-material"},[3](#SD3-data){ref-type="supplementary-material"}).

We further assessed CBF responses to topical application of the endothelium-dependent and smooth muscle-dependent vasodilators, acetylcholine and adenosine, respectively, upon superfusion of TIMP3 (8 and 40 nM), TIMP1 (50 nM) or TIMP2 (50 nM). Again, the increases in CBF induced by acetylcholine or adenosine were profoundly attenuated by TIMP3 but were unaffected by TIMP2 or TIMP1, with the exception of a modest attenuation of the adenosine-induced increase in CBF by TIMP1 ([Figure 1G,H](#fig1){ref-type="fig"}; [Figure 1---figure supplement 2](#fig1s2){ref-type="fig"}; [Figure 1---source data 2](#SD2-data){ref-type="supplementary-material"},[3](#SD3-data){ref-type="supplementary-material"}). Thus, these findings establish that elevation of TIMP3 is sufficient to induce CBF deficits in vivo and suggest that a TIMP3-specific target accounts for these deficits.

ADAM17 is required for TIMP3-induced attenuation of CBF responses {#s2-2}
-----------------------------------------------------------------

Our efforts to identify the target of TIMP3 focused on ADAM17, which is uniquely inhibited by TIMP3 ([@bib50]) and is expressed in brain arteries, as demonstrated by our immunoblot analyses ([Figure 2A,B](#fig2){ref-type="fig"}). If TIMP3 does indeed act through inhibition of ADAM17, its effects on CBF responses should be mimicked by pharmacological inhibition of ADAM17. Here, we used the hydroxamate-based GW413333X inhibitor, which specifically blocks both ADAM10 and ADAM17; the ADAM10 inhibitor GI254023X was used as a control ([@bib17]) ([Figure 2---source data 1](#SD4-data){ref-type="supplementary-material"}). We found that GW413333X (5 µM), but not GI254023X (5 and 20 µM), strongly attenuated the increase in CBF produced by whisker stimulation or topical application of acetylcholine or adenosine ([Figure 2C--E](#fig2){ref-type="fig"}; [Figure 2---figure supplement 1A](#fig2s1){ref-type="fig"}; [Figure 2---source data 2](#SD5-data){ref-type="supplementary-material"},[3](#SD6-data){ref-type="supplementary-material"}). To further support a specific role for ADAM17 in these defects, we assessed CBF responses following reduction of ADAM17 levels using a genetic approach. Complete ablation of ADAM17 is lethal ([@bib38]). Therefore, we used hypomorphic mice with dramatically reduced expression of ADAM17 (*Adam17^ex/ex^*) using the exon-induced translational stop strategy. These mice are viable, but develop eye, skin and heart defects as a consequence of impaired EGFR signaling ([@bib9]). We found that genetic depletion of ADAM17 strongly attenuated CBF responses in a dose-dependent manner ([Figure 2F,G](#fig2){ref-type="fig"}; [Figure 2---figure supplement 1B](#fig2s1){ref-type="fig"}; [Figure 2---source data 2](#SD5-data){ref-type="supplementary-material"},[3](#SD6-data){ref-type="supplementary-material"}). To confirm that the reduction in evoked CBF responses in these mice is caused by reduced ADAM17 expression, we examined whether an enzymatically active extracellular domain of ADAM17 (sADAM17) applied exogenously could prevent these CBF deficits. Topical neocortical application of sADAM17 (16 nM) ([Figure 2---source data 1](#SD4-data){ref-type="supplementary-material"}) did not affect cerebrovascular responses in wild-type mice, but did fully restore CBF responses in *Adam17^ex/+^* mice with half-reduced ADAM17 levels ([Figure 2H--J](#fig2){ref-type="fig"}; [Figure 2---figures supplements 1C](#fig2s1){ref-type="fig"},[2A](#fig2s2){ref-type="fig"}; [Figure 2---source data 2](#SD5-data){ref-type="supplementary-material"},[3](#SD6-data){ref-type="supplementary-material"}). Together, these results indicate that decreasing ADAM17 activity compromises CBF regulation.10.7554/eLife.17536.009Figure 2.Cerebrovascular responses are impaired by pharmacological or genetic inhibition of ADAM17, and rescued by exogenous sADAM17.(**A**) Immunoblot of cerebral arteries dissected from *Adam17^+/+^* and *Adam17^ex/ex^* mice (n = 3 biological samples/genotype) incubated with anti-ADAM17 or anti-smooth muscle α-actin (α-SMA) antibody. (**B**) Quantification of relative protein level of ADAM17 in (**A**). (**C**--**E**) Resting CBF (**C**) and CBF responses to whisker stimulation (**D**) or topical application of adenosine (**E**) were evaluated upon superfusion of the dual ADAM10/ADAM17 inhibitor GW413333X (GW; 5 µM) or the ADAM10 inhibitor GI254023X (GI; 5 and 20 µM). \*\*\*p\<0.05 compared with vehicle. (**F**, **G**) CBF responses to whisker stimulation (**F**) or topical application of adenosine (**G**) were strongly reduced in *Adam17^ex/+^* mice and further reduced in *Adam17^ex/ex^* mice compared with wild-type littermate controls. (**H**--**J**) Exogenous sADAM17 (16 nM) significantly ameliorated CBF responses to whisker stimulation (**I**) or topical application of adenosine (**J**) in *Adam17^ex/+^* mice, whereas ADAM17 had no effect on wild-type littermates. (**K**--**M**) Resting CBF and CBF responses were evaluated in *TgBAC-TIMP3* mice and non-transgenic littermates (WT) before and after superfusion of ADAM17. CBF responses to whisker stimulation (**L**) or topical application of adenosine (**M**) were strongly reduced in *TgBAC-*TIMP3 mice compared with those in WT mice, as previously reported ([@bib6]), and were normalized by sADAM17 superfusion. Significance was determined by one-way ANOVA followed by Tukey's post-hoc test (**B**--**G**) and two-way repeated measure ANOVA followed by Bonferroni post-hoc test (**H**--**M**) (n = 5 mice/group). Error bars indicate SEM.**DOI:** [http://dx.doi.org/10.7554/eLife.17536.009](10.7554/eLife.17536.009)10.7554/eLife.17536.010Figure 2---source data 1.Reagents used for [Figure 2](#fig2){ref-type="fig"}.**DOI:** [http://dx.doi.org/10.7554/eLife.17536.010](10.7554/eLife.17536.010)10.7554/eLife.17536.011Figure 2---source data 2.Main physiological variables of mice studied in [Figure 2](#fig2){ref-type="fig"}.**DOI:** [http://dx.doi.org/10.7554/eLife.17536.011](10.7554/eLife.17536.011)10.7554/eLife.17536.012Figure 2---source data 3.Numerical data that were used to generate the bar charts in [Figure 2](#fig2){ref-type="fig"}.**DOI:** [http://dx.doi.org/10.7554/eLife.17536.012](10.7554/eLife.17536.012)10.7554/eLife.17536.013Figure 2---figure supplement 1.CBF responses to acetylcholine are attenuated by pharmacological or genetic inhibition of ADAM17 but rescued upon superfusion of exogenous sADAM17.(**A**) CBF responses to topical application of acetylcholine were evaluated in 2-month-old wild-type mice upon superfusion of the dual ADAM10/ADAM17 inhibitor GW413333X (GW; 5 µM) or the ADAM10 inhibitor GI254023X (GI; 5 and 20 µM). \*\*\*p\<0.001 compared with vehicle. (**B**) CBF responses to topical application of acetylcholine were strongly reduced in *Adam17^ex^*^/+^ mice and further reduced in *Adam17^ex/ex^* mice compared to littermate wildtype (WT) mice. (**C**) Exogenous soluble active ectodomain of ADAM17 (sADAM17; 16 nM) significantly ameliorated CBF responses to topical application of acetylcholine in *Adam17^ex/+^* mice, whereas it had no effect on wild-type littermates. (**D**) CBF responses to topical application of acetylcholine were strongly reduced in *TgBAC-TIMP3* mice compared with those in WT mice, as previously reported ([@bib6]), and were normalized by sADAM17 superfusion. Significance was determined by one-way ANOVA followed by Tukey's post-hoc test (**A**, **B**) and two-way repeated measure ANOVA followed by Bonferroni post-hoc test (**C**, **D**) (n = 5 mice/group).**DOI:** [http://dx.doi.org/10.7554/eLife.17536.013](10.7554/eLife.17536.013)10.7554/eLife.17536.014Figure 2---figure supplement 2.Absolute measurements of resting CBF in *Adam17^ex/+^*and *TgBAC-TIMP3* mice in the presence and absence of sADAM17.Resting CBF, expressed as Laser Doppler flow arbitrary units (LDFU), was evaluated in *Adam17^ex/+^* mice (**A**), *TgBAC-TIMP3* mice (**B**) and appropriate wild-type littermates, before and after superfusion of soluble ADAM17 (16 nM). Significance was determined by two-way repeated measures ANOVA followed by Bonferroni post-hoc test (n = 5 mice/group).**DOI:** [http://dx.doi.org/10.7554/eLife.17536.014](10.7554/eLife.17536.014)

To further confirm the direct connection between increased TIMP3 expression and reduced ADAM17 activity and CBF deficits, we tested whether exogenous sADAM17 is capable of preventing the CBF deficits produced by genetic overexpression of TIMP3. Superfusion with the enzymatically active extracellular domain of ADAM17 (16 nM) increased resting CBF in *TgBAC-TIMP3* mice towards the same absolute values as wild-type mice and improved all evoked cerebrovascular responses ([Figure 2K--M](#fig2){ref-type="fig"}; [Figure 2---figures supplements 1D](#fig2s1){ref-type="fig"},[2B](#fig2s2){ref-type="fig"}; [Figure 2---source data 2](#SD5-data){ref-type="supplementary-material"},[3](#SD6-data){ref-type="supplementary-material"}) suggesting that TIMP3 induces CBF deficits by decreasing ADAM17 activity.

HB-EGF and EGFR operate downstream of ADAM17 to regulate CBF responses {#s2-3}
----------------------------------------------------------------------

To elucidate the molecular factors that operate downstream of ADAM17 in the context of cerebrovascular regulation, we examined the role of the EGFR signaling pathway. This pathway consists of four related receptor tyrosine kinases of the ErbB family---ErbB1/EGFR (Her1), ErbB2/Neu (Her2), ErbB3 (Her3) and ErbB4 (Her4)---which are regulated by 11 different ligands, all of which are produced as membrane-bound precursor proteins and cleaved by cell surface proteases to yield the active soluble species; ADAM17 is the critical sheddase of at least six of these ligands ([@bib41]; [@bib40]) ([Figure 3A,B](#fig3){ref-type="fig"}). A critical role for ADAM17 in EGFR signaling is supported by the observation that mice deficient for ADAM17 ([@bib38]; [@bib9]) resemble mice lacking EGFR, exhibiting perinatal lethality, generalized epithelial defects, and defective cardiac valves ([@bib32]; [@bib43]; [@bib48]). To investigate the role of the EGFR pathway, we recorded CBF responses evoked by whisker stimulation or vasodilators before and after topical application of blockers of this pathway ([Figure 3---source data 1](#SD7-data){ref-type="supplementary-material"}).10.7554/eLife.17536.015Figure 3.Full CBF responses require ErbB1/ErbB4 and HB-EGF.(**A**, **B**) Schematic representation of the ErbB signaling pathway. Ligands are all produced as membrane-bound precursor proteins that are cleaved by cell-surface sheddases to yield the active growth factor species. Binding of the soluble form of the ligand induces ErbB receptor homodimerization or heterodimerization, converting the receptor to an active dimeric conformation (**A**). Ligands are grouped in four rows according to their receptor specificity (top; arrows); the six ligands for which ectodomain shedding is primarily mediated by ADAM17 appear in black characters, and the remaining five are in grey characters (**B**). (**C**--**K**) Resting CBF (**C**, **F**, **I**) and CBF responses to whisker stimulation (**D**, **G**, **J**) or topical application of adenosine (**E**, **H**, **K**) were evaluated before and after superfusion of various inhibitors of the ErbB signaling pathway, including the ErbB1/ErbB4 inhibitor AG1478 (10 and 20 µM); the ErbB2 inhibitor AG825 (50 and 200 µM) (**C**--**E**), the soluble ErbB receptor traps (ErbB1-Fc, 66.7 nM; ErbB3-Fc, 71.4 nM; ErbB4-Fc, 71.4 nM) and the respective control IgG1-Fc and IgG2-Fc fragments (286 nM) (**F**--**H**), heparin and the synthetic peptide p21 (12 µM) and the control inactive peptide p21-mut (12 µM) (**I**--**K**). None of these compounds affected resting CBF, except ErbB4-Fc, which produced a slight increase. (**C**--**K**) Significance was determined by one-way ANOVA followed by Tukey's post-hoc test (\*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001 compared to vehicle; n = 5/group). Error bars indicate SEM.**DOI:** [http://dx.doi.org/10.7554/eLife.17536.015](10.7554/eLife.17536.015)10.7554/eLife.17536.016Figure 3---source data 1.Reagents used for [Figure 3](#fig3){ref-type="fig"}.**DOI:** [http://dx.doi.org/10.7554/eLife.17536.016](10.7554/eLife.17536.016)10.7554/eLife.17536.017Figure 3---source data 2.Main physiological variables of mice studied in [Figure 3](#fig3){ref-type="fig"}.**DOI:** [http://dx.doi.org/10.7554/eLife.17536.017](10.7554/eLife.17536.017)10.7554/eLife.17536.018Figure 3---source data 3.Numerical data that were used to generate the bar charts in [Figure 3](#fig3){ref-type="fig"}.**DOI:** [http://dx.doi.org/10.7554/eLife.17536.018](10.7554/eLife.17536.018)10.7554/eLife.17536.019Figure 3---figure supplement 1.Blockade of ErbB1/ErbB4 or HB-EGF impairs CBF responses to acetylcholine.(**A**, **B**) CBF responses to application of acetycholine were evaluated before and after superfusion of various inhibitors of the ErbB signaling pathway, including the soluble ErbB receptor traps (ErbB1-Fc, 66.7 nM; ErbB3-Fc, 71.4 nM; ErbB4-Fc, 71.4 nM) and the respective control IgG1-Fc and IgG2-Fc fragments (286 nM) (**A**), heparin and the synthetic peptide p21 (12 µM) and the control inactive peptide p21-mut (12 µM) (**B**). Significance was determined by one-way ANOVA followed by Tukey's post-hoc test. (\*\*\*p\<0.001 compared with vehicle; n = 5 /group).**DOI:** [http://dx.doi.org/10.7554/eLife.17536.019](10.7554/eLife.17536.019)

Based on the decrease in evoked CBF responses to elevation of TIMP3 or reduction of ADAM17, we predicted that inhibition of ErbB pathway would have a similar effect. Indeed, we found that neocortical application of the selective ErbB1/EGFR and ErbB4 inhibitor, tyrphostin AG1478 (10 and 20 µM), strongly attenuated the evoked CBF responses, but did not impair resting CBF. In contrast, CBF responses were unaffected by the selective ErbB2 inhibitor, tyrphostin AG825, at both 50 and 200 µM ([Figure 3C--E](#fig3){ref-type="fig"}; [Figure 3---source data 2](#SD8-data){ref-type="supplementary-material"}, [3](#SD9-data){ref-type="supplementary-material"}). Of note, ErbB3 lacks kinase activity ([@bib40]). We then tested the effect of soluble recombinant decoy ErbB receptors, known as chimeric ErbB receptor traps, which comprise the truncated extracellular domain of the ErbB receptor fused with the constant region (Fc) of human immunoglobulin ([@bib45]). Evoked CBF responses were attenuated by superfusion of either ErbB1/EGFR (67 nM) or ErbB4 (71 nM) receptor traps, which block the function of ErbB1 and ErbB4 ligands, respectively, but not by superfusion of the ErbB3 (71 nM) receptor trap or by control IgG1 Fc (286 nM) and IgG2 Fc (286 nM) fragments ([Figure 3F--H](#fig3){ref-type="fig"}; [Figure 3---figure supplement 1A](#fig3s1){ref-type="fig"}; [Figure 3---source data 2](#SD8-data){ref-type="supplementary-material"}, [3](#SD9-data){ref-type="supplementary-material"}). Notably, the effects of ErbB1 and ErbB4 receptor traps on evoked CBF responses were not additive ([Figure 3G--H](#fig3){ref-type="fig"}; [Figure 3---source data 2](#SD8-data){ref-type="supplementary-material"}, [3](#SD9-data){ref-type="supplementary-material"}), even though neither ErbB1 nor ErbB4 receptor traps achieved maximum inhibition. ErbB2 has no known ligand ([@bib40]); thus, these data are consistent with a role for ErbB1/EGFR or ErbB4 activation in CBF responses, and suggest the involvement of bispecific ligands with dual-specificity toward ErbB1 and ErbB4.

Next, we sought to pinpoint which ErbB ligand that requires *ADAM17* cleavage for activation is involved in CBF regulation. Heparin-binding EGF-like growth factor (HB-EGF) is one of three ligands that can bind to both ErbB1 and ErbB4 and is expressed in the vasculature ([@bib53]). ADAM17 is the major sheddase of HB-EGF ([@bib41]), and ADAM17-mediated shedding of proHB-EGF largely regulates soluble, mature HB-EGF binding to and activating ErbB receptors ([@bib51]). Moreover, mice lacking HB-EGF have reduced postnatal viability with defective cardiac valvulogenesis, similar to mice lacking ADAM17 ([@bib21]), prompting us to study the role of HB-EGF in cerebrovascular regulation. To do this, we examined the impact of HB-EGF inhibition on CBF responses. Unlike all other EGF ligands apart from amphiregulin, HB-EGF has a heparin-binding domain, and interactions through this domain with cell surface-associated heparan sulfate proteoglycans (HSPGs) are necessary for binding and activation of ErbB receptors ([@bib15]). We found that superfusion of heparin (40 ui/mL), which competitively inhibits binding of HB-EGF to cell surface HSPGs ([@bib15]), impaired evoked CBF responses without affecting resting CBF ([Figure 3I--K](#fig3){ref-type="fig"}; [Figure 3---figure supplement 1B](#fig3s1){ref-type="fig"}; [Figure 3---source data 2](#SD8-data){ref-type="supplementary-material"}, [3](#SD9-data){ref-type="supplementary-material"}). To further support a role for HB-EGF in evoked CBF responses, we examined the effects of the synthetic peptide p21, which corresponds to the heparin-binding domain of murine HB-EGF and similarly inhibits binding of HB-EGF to cell surface HSPGs ([@bib15]). We found that superfusion of p21 (12 µM) similarly impaired evoked CBF responses without affecting resting CBF ([Figure 3I--K](#fig3){ref-type="fig"}; [Figure 3---figure supplement 1B](#fig3s1){ref-type="fig"}; [Figure 3---source data 2](#SD8-data){ref-type="supplementary-material"}, [3](#SD9-data){ref-type="supplementary-material"}); in contrast, a mutated inactive p21 peptide (p21-mut; 12 µM) had no effect on evoked or resting CBF.

To assess the connection between HB-EGF and ADAM17 in the context of cerebrovascular regulation, we tested the ability of a soluble form of HB-EGF (sHB-EGF) to counteract cerebrovascular dysfunction induced by ADAM17 inhibition or depletion ([Figure 4---source data 1](#SD10-data){ref-type="supplementary-material"}). TIMP3 or the ADAM10/17 inhibitor, GW413333X, was topically applied over the neocortex and CBF responses were measured before and after superfusion with sHB-EGF. We found that sHB-EGF (20 nM) prevented TIMP3 and GW-induced cerebrovascular deficits ([Figure 4D--I](#fig4){ref-type="fig"}; [Figure 4---figure supplement 1A,B](#fig4s1){ref-type="fig"}; [Figure 4---source data 2](#SD11-data){ref-type="supplementary-material"},[3](#SD12-data){ref-type="supplementary-material"}). Also, sHB-EGF significantly improved evoked CBF responses in *Adam17^ex/ex^* mice ([Figure 4---figure supplement 2](#fig4s2){ref-type="fig"}). Notably, sHB-EGF could not prevent CBF deficits induced by pharmacological blockage of ErbB1/EGFR and ErbB4 ([Figure 4A--C](#fig4){ref-type="fig"}; [Figure 4---source data 1](#SD10-data){ref-type="supplementary-material"}--[3](#SD12-data){ref-type="supplementary-material"}). These findings, collectively, suggest that ADAM17/HB-EGF/(ErbB1/ErbB4) is a key TIMP3-sensitive signaling pathway for cerebrovascular regulation.10.7554/eLife.17536.020Figure 4.sHB-EGF overcomes CBF deficits induced by ADAM17 inhibition.Effects of sHB-EGF (20 nM) on resting CBF (**A**, **D**, **G**) and whisker stimulation (**B**, **E**, **H**)- and adenosine (**C**, **F**, **I**)-induced CBF responses were assessed in the presence and absence of the ErbB1/ErbB4 inhibitor AG1478 (10 and 20 µM) (**A**--**C**), TIMP3 (40 nM) (**D**--**F**) or the ADAM10/ADAM17 inhibitor GW413333X (GW; 5 µM) (**G**--**I**) using a cranial window model. Significance was determined by repeated measure ANOVA followed by Tukey's post-hoc test (\*p\<0.05, \*\*\*p\<0.001 compared to vehicle; ^\#\#\#^p\<0.001 TIMP3+sHB-EGF versus TIMP3 and GW+sHB-EGF versus GW; n = 5/group). Error bars indicate SEM.**DOI:** [http://dx.doi.org/10.7554/eLife.17536.020](10.7554/eLife.17536.020)10.7554/eLife.17536.021Figure 4---source data 1.Reagents used for [Figure 4](#fig4){ref-type="fig"}.**DOI:** [http://dx.doi.org/10.7554/eLife.17536.021](10.7554/eLife.17536.021)10.7554/eLife.17536.022Figure 4---source data 2.Main physiological variables of mice studied in [Figure 4](#fig4){ref-type="fig"}.**DOI:** [http://dx.doi.org/10.7554/eLife.17536.022](10.7554/eLife.17536.022)10.7554/eLife.17536.023Figure 4---source data 3.Numerical data that were used to generate the bar charts in [Figure 4](#fig4){ref-type="fig"}.**DOI:** [http://dx.doi.org/10.7554/eLife.17536.023](10.7554/eLife.17536.023)10.7554/eLife.17536.024Figure 4---figure supplement 1.Acetylcholine-induced CBF responses impaired by ADAM17 inhibition are ameliorated by exogenous sHB-EGF.(**A**, **B**) Effects of sHB-EGF (20 nM) on acetylcholine-induced CBF responses were assessed in the presence and absence of TIMP3 (40 nM) (**A**) or the ADAM10/ADAM17 inhibitor GW413333X (GW; 5 µM) (**B**). \*\*\*p\<0.001 compared to vehicle; ^\#\#\#^p**DOI:** [http://dx.doi.org/10.7554/eLife.17536.024](10.7554/eLife.17536.024)10.7554/eLife.17536.025Figure 4---figure supplement 2.CBF deficits induced by ADAM17 deficiency are improved by sHB-EGF.Effects of sHB-EGF (20 nM) on resting CBF (**A**) and whisker stimulation (**B**) and adenosine (**C**)-induced CBF responses were assessed in Adam17^ex/ex^ and wildtype littermate (Adam17^+/+^) mice. Significance was determined by repeated measure ANOVA followed by Bonferroni post-hoc test (\*\*p\< 0.01, \*\*\*p\<0.001; n = 5/group).**DOI:** [http://dx.doi.org/10.7554/eLife.17536.025](10.7554/eLife.17536.025)

The ADAM17/HB-EGF/(ErbB1/ErbB4) signaling module regulates pressure-induced myogenic tone in brain arteries {#s2-4}
-----------------------------------------------------------------------------------------------------------

Our data support the concept that the ADAM17/HB-EGF/(ErbB1/ErB4) axis regulates CBF responses, and any genetic or pharmacological maneuver that inhibits this pathway impairs CBF responses to diverse stimuli, including topical application of vasodilators and neural activity ([Figures 1](#fig1){ref-type="fig"}--[3](#fig3){ref-type="fig"}). Notably, responses cannot be enhanced by stimulation of this pathway, implying that this pathway is maximally activated in a physiological in vivo setting. Given that myogenic tone sets the resting arterial diameter from which other stimuli can induce vasoconstriction or vasodilation, we hypothesized that a reduction in the myogenic tone of cerebral arteries could represent a common mechanism underlying these CBF deficits. To test this hypothesis, we assessed the effects of inhibitors of this pathway on pressure-induced constriction of brain arteries ([Figure 5---source data 1](#SD13-data){ref-type="supplementary-material"}).

We found that pre-incubation of arterial segments with TIMP3 (8 nM) strongly attenuated myogenic tone at pressures of 40 mmHg and above compared to arteries incubated with vehicle, whereas recombinant TIMP2 (10 nM) had no effect ([Figure 5A--C](#fig5){ref-type="fig"}; [Figure 5---source data 2](#SD14-data){ref-type="supplementary-material"}). Notably, attenuation of myogenic responses by TIMP3 was even more pronounced in intracerebral penetrating arterioles ([Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}). Likewise, myogenic constriction to pressure was strongly attenuated by the dual ADAM10/ADAM17 inhibitor GW413333X (1 µM), but not by the ADAM10 inhibitor GI254023X (1 µM). Also, myogenic tone was reduced in heterozygous ADAM17 hypomorphic mice (*Adam17^ex/+^*) compared to wild-type littermates (*Adam17^+/+^*) but restored by pre-incubating arterial segments of *Adam17^ex/+^*mice with sADAM17 (3.2 nM) ([Figure 5D,I](#fig5){ref-type="fig"}; [Figure 5---figure supplement 2](#fig5s2){ref-type="fig"}; [Figure 5---source data 2](#SD14-data){ref-type="supplementary-material"}). Moreover, pre-incubation of arteries with the ErbB1/ErbB4 inhibitor AG1478 (2 µM) or the HB-EGF inhibitor p21 peptide (2.4 µM), but not with the p21-mut peptide (2.4 µM), strongly attenuated myogenic responses ([Figure 5E,F](#fig5){ref-type="fig"}; [Figure 5---source data 2](#SD14-data){ref-type="supplementary-material"}). Thus, these data indicate that myogenic tone is increased by tonic activity of the ADAM17/HB-EGF/(ErbB1/ErbB4) pathway.10.7554/eLife.17536.026Figure 5.The ADAM17/HB-EGF/(ErbB1/ErbB4) signaling module is involved in regulating the myogenic tone of cerebral arteries.([**A**]{.smallcaps}--**C**) Effects of TIMP proteins on the myogenic responses of posterior cerebral arteries to increasing intraluminal pressure. (**A**, **B**) Representative internal diameter recordings in the presence of TIMP2 (10 nM) (**A**) or TIMP3 (8 nM) (**B**). (**C**) Summary data of results in (**A**) and (**B**). (**D**--**F**) Myogenic tone of posterior cerebral arteries, tested in the presence and absence of the dual ADAM10/ADAM17 inhibitor GW413333X (GW; 1 µM), the ADAM10 inhibitor GI254023X (GI; 1 µM) (**D**), the ErbB1/ErbB4 inhibitor AG1478 (2 µM) (**E**), the p21 peptide (2.4 µM), and the mutated inactive peptide p21-mut (2.4 µM) (**F**). (**C**--**F**) \*\*p\<0.01, \*\*\*p\<0.001 versus vehicle. (**G**, **H**) Effects of TIMP3 (8 nM) (g) or GW (1 µM) (**H**) on the myogenic tone of posterior cerebral arteries were tested in the presence of soluble HB-EGF (3 nM) or vehicle. ^\#\#^p\<0.01, ^\#\#\#^p\<0.001, TIMP3+HB-EGF versus TIMP3 and GW+HB-EGF versus GW. (**I**) Myogenic tone of posterior cerebral arteries was tested in heterozygous *Adam17^ex/+^* (ex/wt) and *Adam17^+/+^*(wt/wt) mice in the presence and absence of soluble HB-EGF (3 nM). \*\*p\<0.01, \*\*\*p\<0.001 *Adam17^ex/+^* versus *Adam17^+/+^*; ^\#\#^p\<0.01, ^\#\#\#^p\<0.001, *Adam17^ex/+^*/HB-EGF versus *Adam17^ex/+^*). Significance was determined by two-way repeated measures ANOVA followed by Bonferroni post-hoc test (n = 6--8 arteries/group). Error bars indicate SEM.**DOI:** [http://dx.doi.org/10.7554/eLife.17536.026](10.7554/eLife.17536.026)10.7554/eLife.17536.027Figure 5---source data 1.Reagents used for [Figure 5](#fig5){ref-type="fig"}.**DOI:** [http://dx.doi.org/10.7554/eLife.17536.027](10.7554/eLife.17536.027)10.7554/eLife.17536.028Figure 5---source data 2.Numerical data that were used to generate the graphs in [Figure 5](#fig5){ref-type="fig"}.**DOI:** [http://dx.doi.org/10.7554/eLife.17536.028](10.7554/eLife.17536.028)10.7554/eLife.17536.029Figure 5---figure supplement 1.TIMP3 strongly impairs myogenic tone of parenchymal arterioles.(**A**--**C**) Effects of TIMP proteins on the myogenic responses of parenchymal arterioles to increasing intraluminal pressure. (**A**, **B**) Representative internal diameter recordings in the presence of TIMP2 (10 nM) (**A**) or TIMP3 (8 nM) (**B**). (**C**) Summary data of results in (**A**) and (**B**). Significance was determined by two-way repeated measures ANOVA followed by Bonferroni post-hoc test. (\*\*p\<0.01, \*\*\*\*p\<0.0001 n = 8 arterioles/group).**DOI:** [http://dx.doi.org/10.7554/eLife.17536.029](10.7554/eLife.17536.029)10.7554/eLife.17536.030Figure 5---figure supplement 2.sADAM17 ameliorates arterial tone in *Adam17^ex/+^*mice.Myogenic tone of posterior cerebral arteries was tested in heterozygous *Adam17^ex/+^* in the presence and absence of soluble ADAM17 (3.2 nM). Significance was determined by two-way repeated measures ANOVA followed by Bonferroni post-hoc test (\*\*p\< 0.01, \*\*\*p\<0.001, \*\*\*\*p\<0.0001. n = 5--6 arteries/group).**DOI:** [http://dx.doi.org/10.7554/eLife.17536.030](10.7554/eLife.17536.030)

To provide further support for the concept that ADAM17 and HB-EGF function as part of a signaling module to enhance the myogenic tone of cerebral arteries, we tested the ability of exogenous sHB-EGF to counteract the effects of ADAM17 inhibition ([Figure 5---source data 1](#SD13-data){ref-type="supplementary-material"}). Pressurized arteries were pre-incubated with recombinant TIMP3 (4 nM) or the ADAM10/ADAM17 inhibitor GW413333 in the presence of sHB-EGF (3 nM) or vehicle. We found that co-incubation of arterial segments with sHB-EGF significantly ameliorated the TIMP3-induced reduction in arterial tone ([Figure 5G](#fig5){ref-type="fig"}; [Figure 5---source data 2](#SD14-data){ref-type="supplementary-material"}). Likewise, co-incubation of arterial segments with sHB-EGF overcame the reduction in arterial tone caused by GW413333-mediated inhibition of ADAM17 ([Figure 5H](#fig5){ref-type="fig"}; [Figure 5---source data 2](#SD14-data){ref-type="supplementary-material"}). Moreover, sHB-EGF significantly increased myogenic tone in arteries from heterozygous ADAM17-hypomorphic mice (*Adam17^ex/+^*), restoring a near-normal myogenic phenotype ([Figure 5I](#fig5){ref-type="fig"}; [Figure 5---source data 2](#SD14-data){ref-type="supplementary-material"}). Collectively, these data support the concept that the TIMP3-sensitive pathway, ADAM17/HB-EGF/(ErbB1/ErbB4), increases myogenic constriction in brain arteries.

Exogenous sADAM17 and exogenous sHB-EGF rescue CBF and myogenic-response deficits in the *TgNotch3^R169C^ *CADASIL model {#s2-5}
------------------------------------------------------------------------------------------------------------------------

Our findings above predict that excess TIMP3 impairs arterial tone and CBF responses in CADASIL by suppressing the ADAM17/HB-EGF/(ErbB1/ErbB4) pathway. To test this, we examined whether recombinant sADAM17 and sHB-EGF could restore normal pressure-induced myogenic constriction of brain arteries and normal cerebrovascular responses in *TgNotch3^R169C^* CADASIL mice. We found that preincubation of arterial segments with the enzymatically active extracellular domain of ADAM17 (3.2 nM) increased myogenic tone in arteries from *TgNotch3^R169C^* CADASIL mice, whereas sADAM17 had no detectable effect on arterial segments from wild-type mice at this concentration ([Figure 6A](#fig6){ref-type="fig"}). We further found that sADAM17 (16 nM), locally applied on the necortex of *TgNotch3^R169C^* CADASIL mice, significantly improved resting CBF and rescued the impaired reactivity of brain vessels to whisker stimulation and vasodilators ([Figure 6B--D](#fig6){ref-type="fig"}; [Figure 6---figure supplement 1](#fig6s1){ref-type="fig"}; [Figure 6---source data 1](#SD15-data){ref-type="supplementary-material"},[2](#SD16-data){ref-type="supplementary-material"}). We previously reported that sHB-EGF restores myogenic responses in parenchymal arteries from *TgNotch3^R169C^* CADASIL mice ([@bib12]). Here, we extend these observations, showing that exogenous sHB-EGF (20 nM) restored evoked CBF responses in *TgNotch3^R169C^* mice ([Figure 6E--G](#fig6){ref-type="fig"}; [Figure 6---source data 1](#SD15-data){ref-type="supplementary-material"},[2](#SD16-data){ref-type="supplementary-material"}). Collectively, these findings support the concept that the diminished myogenic tone and CBF deficits in CADASIL are caused by TIMP3-mediated suppression of the ADAM17/HB-EGF/(ErbB1/ErbB4) pathway.10.7554/eLife.17536.031Figure 6.Exogenous sADAM17 and sHB-EGF ameliorate CBF deficits and arterial tone in *TgNotch3^R169C^* mice.(**A**) Myogenic tone of posterior cerebral arteries from *TgNotch3^R169C^* mice (TgN3^R169C^) and non-transgenic littermates (WT) was tested in the presence of soluble ADAM17 or vehicle. \*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001 versus WT+vehicle; ^\#^p\<0.05, ^\#\#^p\<0.01, ^\#\#\#^p\<0.001 TgN3^R169C^+vehicle versus TgN3^R169C^+sADAM17 (n = 5--7 arteries/ group; 1 artery/mouse). (**B**--**D**) Resting CBF (**B**) and CBF responses to whisker stimulation (**C**) or adenosine (**D**) were tested in TgN3^R169C^ and WT mice, before and after superfusion of soluble ADAM17. ([**E**]{.smallcaps}--**G**) Effects of soluble HB-EGF tested in a second batch of TgN3^R169C^ and WT mice. Significance was determined by two-way repeated measures ANOVA followed by Bonferroni post-hoc test (n = 5--6 mice/group). Error bars indicate SEM.**DOI:** [http://dx.doi.org/10.7554/eLife.17536.031](10.7554/eLife.17536.031)10.7554/eLife.17536.032Figure 6---source data 1.Main physiological variables of mice studied in [Figure 6](#fig6){ref-type="fig"}.**DOI:** [http://dx.doi.org/10.7554/eLife.17536.032](10.7554/eLife.17536.032)10.7554/eLife.17536.033Figure 6---source data 2.Numerical data that were used to generate the graphs and bar charts in [Figure 6](#fig6){ref-type="fig"}.**DOI:** [http://dx.doi.org/10.7554/eLife.17536.033](10.7554/eLife.17536.033)10.7554/eLife.17536.034Figure 6---figure supplement 1.Resting CBF and acetylcholine-induced CBF responses impaired by the R169C Notch3 mutation are ameliorated by exogenous sADAM17.Resting CBF, expressed as Laser Doppler flow arbitrary units (LDFU) (**A**) and CBF responses to acetylcholine (**B**) were tested in TgNotch3^R169C^ mice (TgN3^R169C^) and non-transgenic littermates (WT) before and after superfusion of sADAM17 (16 nM). \*\*\*p\<0.001. Significance was determined by two-way repeated measures ANOVA followed by Bonferroni post-hoc test (n = 5--6 mice/group).**DOI:** [http://dx.doi.org/10.7554/eLife.17536.034](10.7554/eLife.17536.034)

Excess TIMP3 drives upregulation of K~V~ currents in cerebral arterial myocytes from *TgNotch3^R169C^ *mice {#s2-6}
-----------------------------------------------------------------------------------------------------------

Our prior work established that upregulation of K~V~ channels in the plasma membrane of cerebral arterial myocytes is responsible for the diminished myogenic response of cerebral arteries in the *TgNotch3^R169C^ *CADASIL model. Importantly, application of sHB-EGF was found to normalize K~V~ current density and restore myogenic responses in cerebral arteries from *TgNotch3^R169C^*mice ([@bib12]). In light of this and the above, we investigated the involvement of TIMP3 and ADAM17 in this upregulation of K~V~ current density.

We first asked whether reducing TIMP3 expression in the *TgNotch3^R169C ^*mice would decrease the number of functional K~V~ channels. To this end, we measured K~V~ currents in freshly isolated myocytes from cerebral arteries of *TgNotch3^R169C ^*mice with normal expression of TIMP3 (*TgNotch3^R169C^;Timp3^+/+^*), which have reduced myogenic tone, and in freshly isolated myocytes from cerebral arteries of *TgNotch3^R169C ^*mice with reduced expression of TIMP3 (*TgNotch3^R169C^;Timp3^+/-^)*, in which myogenic responses are restored ([@bib12]). Currents were recorded in response to 10-mV voltage steps from −70 mV to +60 mV. We found that K~V~ current density was significantly lower in myocytes from *TgNotch3^R169C^;Timp3^+/-^* mice than in myocytes from *TgNotch3^R169C^;Timp3^+/+^* at all voltage steps above +10 mV ([Figure 7A--C](#fig7){ref-type="fig"}; [Figure 7---source data 2](#SD18-data){ref-type="supplementary-material"}). Conversely, incubation of wild-type arterial myocytes with recombinant TIMP3 (8 nM) resulted in a significant increase in K~V~ current density compared with myocytes incubated with vehicle ([Figure 7---figure supplement 1A,B](#fig7s1){ref-type="fig"}; [Figure 7---source data 2](#SD18-data){ref-type="supplementary-material"}). Remarkably, half-maximal activation voltage (V~0.5~) and slope (k), determined by fitting normalized peak tail currents to the Boltzmann equation, were statistically indistinguishable among arterial myocytes from the different groups analyzed. Likewise, activation (τ~act~) and deactivation (τ~deact~) time constants determined from exponential fits of individual voltage-evoked current traces and current decay, respectively, were comparable among the different groups. These current kinetics, attributable to K~V~1.5 channels, are consistent with our previous report ([@bib12]). These results indicate that the TIMP3 pathway regulates the number of channels, and not channel properties ([Figure 7---figure supplement 2](#fig7s2){ref-type="fig"}; [Figure 7---source data 1](#SD17-data){ref-type="supplementary-material"},[2](#SD18-data){ref-type="supplementary-material"}). Using the Goldman--Hodgkin--Katz constant field equation and a single-channel conductance of 15 pS ([@bib1]), we estimated the average number of functional K~V~ channels per myocyte. This analysis showed that exogenously applied TIMP3 increased the number of K~V~ channels in arteries from wild-type mice by \~25% (from 3120 to 3920 per myocyte). A similar increase in K~V~ channel number was observed in the TIMP3-overexpressing *TgNotch3^R169C^;Timp3^+/+^* genetic model, where channel density (4840/myocyte) was \~38% greater than that in *TgNotch3^R169C^;Timp3^+/-^* mice (3510/myocyte).10.7554/eLife.17536.035Figure 7.TIMP3 haploinsufficiency and exogenous sADAM17 decrease K~V~ channel current density in cerebral smooth muscle cells from *TgNotch3^R169C^* mice.(**A**,**B**) Typical family of K~V~ currents recorded in isolated cerebral smooth muscle cells from double-mutant *TgNotch3^R169C^;Timp3^+/-^* mice, with *Timp3* haploinsufficiency in the context of *Notch3^R169C^* overexpression (**B**), and *TgNotch3^R169C^;Timp3^+/+^* mice, with wild-type *Timp3* in the context of *Notch3^R169C^* overexpression (**A**) elicited by voltage pulses from −70 mV to +60 mV in the presence of 1 μM paxilline (included to block BK channel currents). (**C**) Summary of current density results, showing that current density is decreased in myocytes of *TgNotch3^R169C^;Timp3^+/-^* mice compared with those of *TgNotch3^R169C^;Timp3^+/+^* mice. (**D**) Typical family of K~V~ currents recorded in isolated cerebral smooth muscle cells from *TgNotch3^R169C^* mice incubated with soluble ADAM17 (3.2 nM). (**E**) Summary of current density results, showing that the current density of *TgNotch3^R169C^* mice is decreased in the presence of sADAM17. Significance was analyzed by two-way repeated measures ANOVA followed by Bonferroni post-hoc test (n = 7--8 cells/group; 1 cell/mouse). Error bars indicate SEM.**DOI:** [http://dx.doi.org/10.7554/eLife.17536.035](10.7554/eLife.17536.035)10.7554/eLife.17536.036Figure 7---source data 1.Comparison of cerebral K~V~ current properties.**DOI:** [http://dx.doi.org/10.7554/eLife.17536.036](10.7554/eLife.17536.036)10.7554/eLife.17536.037Figure 7---source data 2.Numerical data that were used to generate the graphs in [Figure 7](#fig7){ref-type="fig"}.**DOI:** [http://dx.doi.org/10.7554/eLife.17536.037](10.7554/eLife.17536.037)10.7554/eLife.17536.038Figure 7---figure supplement 1.Exogenous TIMP3 increases voltage-gated potassium (K~V~) channel current density in cerebral smooth muscle cells.(**A**) Typical family of K~V~ currents recorded in isolated cerebral smooth muscle cells from non-Tg (WT) mice incubated with TIMP3 (8 nM) or vehicle and elicited by voltage pulses from −70 mV to +60 mV in the presence of 1 μM paxilline (included to block BK channel currents). (**B**) Summary of current density results, showing that exogenous TIMP3 increases current density. Significance was analyzed by two-way repeated measures ANOVA followed by Bonferroni post-hoc test (n = 5 cells /group; 1 cell/mouse).**DOI:** [http://dx.doi.org/10.7554/eLife.17536.038](10.7554/eLife.17536.038)10.7554/eLife.17536.039Figure 7---figure supplement 2.Analyses of cerebral K~V~ current properties.(**A**) Activation time constants (τ~activation~) were determined from an exponential fit of individual voltage-evoked current traces. (**B**) De-activation time constants (τ~deactivation~), obtained from an exponential fit of tail currents at −40 mV. (**C**) Steady-state activation properties of K~V~ currents measured from normalized tail currents. The voltage for half-maximal activation (V~1/2~) and the factor k were obtained from a fit of the data to the Boltzman equation.**DOI:** [http://dx.doi.org/10.7554/eLife.17536.039](10.7554/eLife.17536.039)

Our model predicts that exogenous sADAM17 should counteract the increase in TIMP3 in cerebral arteries of *TgNotch3^R169C^*mice by decreasing K~V~ channel density. Consistent with the ability of exogenous sADAM17 to restore normal myogenic responses in *TgNotch3^R169C^* mice, we found that application of enzymatically active, sADAM17 (3.2 nM) significantly reduced K~V~ current density in *TgNotch3^R169C^* cerebral myocytes, decreasing the density of Kv channels by \~22% (from 4840 to 3760 channels per myocyte) ([Figure 7D,E](#fig7){ref-type="fig"}; [Figure 7---source data 2](#SD18-data){ref-type="supplementary-material"}). Thus, these new findings, taken together with our previous studies, indicate that excess TIMP3 in the *TgNotch3^R169C^*CADASILmodel drives increased K~V~ channel density and diminished myogenic responses by reducing ADAM17 activity and subsequently reducing the release of sHB-EGF.

Discussion {#s3}
==========

Although SVD of the brain is a heterogeneous group of disorders with different ultimate causes acting through specific pathways, the recently emerging view is that perturbations of proteins constituting or associated with the extracellular matrix of cerebral vessels could be a convergent pathway driving the functional and structural alterations of small brain vessels ([@bib25]). Previously, we demonstrated that elevated TIMP3, a protein tightly bound to the extracellular matrix of brain arteries, contributes to cerebrovascular dysfunction in CADASIL, a genetic paradigm of small vessel disease of the brain ([@bib33]; [@bib6]). In the present study, we establish the novel concept that a TIMP3-sensitive pathway is constitutively engaged in the regulation of cerebral hemodynamics, and we unravel the mechanism by which excess TIMP3 in brain vessels compromises cerebrovascular regulation in a clinically relevant model of CADASIL.

By combining genetic and pharmacological approaches with in vivo analyses of CBF regulation and ex vivo measurements of myogenic responses of brain arteries in physiological settings, we found that ADAM17/HB-EGF/(ErbB1/ErbB4) is a key TIMP3-sensitive signaling module essential for maintaining robust CBF responses to evoked neural activity or topically applied vasodilators as well as for myogenic responses of brain arteries. Next, using the *TgNotch3^R169C ^*model, we provided pharmacological evidence that, in the setting of CADASIL, attenuated ADAM17 and HB-EGF-dependent activation of ErbB1/ErbB4 underlies deficits in evoked CBF responses and cerebral arterial tone. Further, by using patch clamp electrophysiology in combination with genetic and pharmacological approaches, we identified upregulated K~V~ channel current density in cerebral arterial myocytes as the heretofore-unrecognized downstream effector of this TIMP3-sensitive pathway by which excess TIMP3 reduces arterial tone in the *TgNotch3^R169C ^*CADASIL model. Collectively, these data suggest that elevated TIMP3 blunts the activity of the ADAM17/HB-EGF/(ErbB1/ErbB4) pathway in cerebral arterial myocytes, thereby attenuating myogenic responses in brain arteries and compromising CBF regulation in CADASIL ([Figure 8](#fig8){ref-type="fig"}).10.7554/eLife.17536.040Figure 8.Proposed model of TIMP3 regulation of cerebral arterial tone and CBF responses.(**A**) Under physiological conditions (upper panel), TIMP3 is present in a low abundance in the extracellular matrix of brain arteries. ADAM17 at the cell surface of cerebral arterial myocytes is therefore active and able to cleave and release sHB-EGF, resulting in ErbB1/ErbB4 activation and K~V~1 channel endocytosis. The internalization of K~V~1 channels relieves the tonic hyperpolarizing influence of these channels on the membrane potential of arterial myocytes, thereby allowing full development of pressure-induced vasoconstriction (myogenic tone) of brain arteries and enabling full CBF responses to whisker stimulation and vasodilators. (**B**) In CADASIL (lower panel), Notch3^ECD^ accumulates at the surface of smooth muscle cells, leading to an increase in the amount of TIMP3, which binds to and inhibits ADAM17, blunting sHB-EGF release and ErbB1/ErbB4 activity, and thereby decreasing K~V~1 endocytosis. The resulting increase in K~V~1 current density hyperpolarizes arterial myocytes, acting as a brake to limit the development of myogenic tone and evoked CBF responses.**DOI:** [http://dx.doi.org/10.7554/eLife.17536.040](10.7554/eLife.17536.040)

Our data provide the first evidence for a mechanistic link between a change in a component of the extracellular matrix of cerebral arteries---TIMP3---and a pathogenic alteration in the density of an ion channel---K~V~---in cerebral arterial myocytes. K~V~ channels are powerful negative regulators of arterial tone, which act by exerting a tonic hyperpolarizing influence on the membrane potential of arterial smooth muscle cells that serves to limit pressure-induced depolarization and vasoconstriction ([@bib31]). Our results introduce the novel concept that the concentration of TIMP3 in brain vessels regulates arterial tone and blood flow by playing a critical role in adjusting K~V~ channel density. We surmise that such an extracellular matrix-dependent paradigm may be at play in more common forms of cerebral small vessel disease where remodeling of the vascular extracellular matrix is a key feature ([@bib25]).

Our results indicate that, under physiological conditions, tonic activity of the ADAM17/HB-EGF/(ErbB1/ErbB4) pathway prevents excess accumulation of K~V~ channels at the plasma membrane and thereby maintains myogenic tone and robust CBF responses to neural activity and vasodilators. Interestingly, we found that only factors that inhibit this pathway had a functional effect; activating this pathway in wild-type mice by providing sADAM17 or sHB-EGF did not enhance evoked CBF responses or myogenic tone. This suggests that the set point of this pathway in a physiological in vivo setting is already at maximum. In support of this interpretation is a recent study showing that genetic overexpression of ADAM17 protein does not result in enhanced shedding activity in vivo ([@bib52]). On the other hand, decreasing K~V~ current density in cerebral artery myocytes, which is at least 50% lower than that in peripheral artery myocytes ([@bib12]), could be an in vivo rate-limiting step following physiological activation of this pathway. Notably however, studies in experimental models of aneurysmal subarachnoid hemorrhage indicate that this pathway can be further activated in a pathological context. Indeed, Wellman and colleagues have shown that the blood component, oxyhemoglobin, causes suppression of K~V~ currents in cerebral arterial myocytes through HB-EGF--mediated activation of ErbB1/ErbB4, resulting in membrane depolarization and enhanced tone of brain arteries ([@bib35]).

In the present study, we found that any genetic or pharmacological maneuver that blocked the ADAM17/HB-EGF/(ErbB1/ErbB4) pathway attenuated both the myogenic tone of brain arteries and the increase in CBF responses evoked by diverse stimuli; conversely, exogenous sADAM17 and sHB-EGF could overcome the reduction in both myogenic tone and evoked CBF responses elicited by the R169C Notch3 mutation or elevated TIMP3. Moreover, our previous ([@bib12]) and current results collectively indicate that upregulation of K~V~ channels is sufficient to explain the decrease in myogenic tone, without an involvement of the endothelium or large conductance, voltage and Ca^2+^ activated K^+^ (BK) channels. Nonetheless, we cannot exclude an effect on other channels engaged by pressure. Given the key role of K~V~ channels in the regulation of arterial tone, these findings are consistent with the interpretation that the smooth muscle ADAM17/HB-EGF/(ErbB1/ErbB4)/K~V~ pathway regulates evoked CBF responses by elevating the physiological tone of brain arteries, and that the reduction in myogenic tone caused by inhibition of this pathway by excess TIMP3 in the extracellular matrix surrounding smooth muscle cells likely accounts for the attenuation of evoked CBF responses in CADASIL ([Figure 8](#fig8){ref-type="fig"}). A previous study in acute brain slices provides additional support for this interpretation, showing that the initial degree of arteriolar tone determines the diameter changes elicited by functional hyperemia ([@bib3]). On the other hand, a transient loss of myogenic tone is expected to increase resting CBF, and vice versa. Unexpectedly, we found that acute pharmacological blockade of the ADAM17/HB-EGF/(ErbB1/ErbB4) pathway did not affect resting CBF (or inconsistently increased it), despite its ability to profoundly reduce myogenic responses of brain arteries ex vivo. Also, neocortical application of exogenous sADAM17 unexpectedly increased resting CBF in *TgNotch3^R169C^*mice, despite its ability to increase and normalize myogenic tone in these mice. However, although myogenic tone and myogenic responses are known to contribute to the regulation of resting CBF, their relative importance are hard to quantify and poorly understood; their contribution may also change depending on conditions or disease states and other mechanisms ---metabolic, neural, endothelial---also influence or contribute to resting CBF ([@bib11]). It is also possible that overall resting CBF does not change despite seeing a change in myogenic tone in one portion of the vasculature because of compensatory adjustments in vessels downstream. Simultaneous in vivo recordings of blood flow and vessel diameters may be of interest to address this possibility. Moreover, it should be stressed that in our experiments cell populations targeted by pharmacological compounds likely differ depending on whether the compound is topically applied in vivo over the somatosensory cortex or incubated ex vivo with isolated brain arteries. In particular, proteins or peptides topically applied in vivo are thought to target only the abluminal surface of the vessel (smooth muscle cells) ([@bib37]) and may target other brain cells (e.g., astrocytes), whereas ex vivo incubation targets only vascular cells, including both abluminal and luminal (endothelial cell) surfaces. In this regard, involvement of the ADAM17/HB-EGF/(ErbB1/ErbB4) pathway in cells other than arterial myocytes cannot be ruled out. Finally, our results may point toward the involvement of other downstream effectors in addition to K~V~ channels in the regulation of CBF by this pathway.

The fact that increasing TIMP3 or decreasing ADAM17 caused a concentration-dependent impairment of cerebrovascular function taken together with the observation that exogenous sADAM17 is capable of overcoming elevated TIMP3-induced cerebrovascular dysfunction indicates that ADAM17 activity depends on the relative activity of ADAM17 and TIMP3 in brain arteries. Several lines of evidence from cell systems indicate that the bulk of ADAM17 is intracellular, whereas the majority of ADAM17 shedding activity occurs at the cell surface, where ADAM17 can associate with its natural inhibitor TIMP3 ([@bib50]; [@bib10]). Thus, the ratio of TIMP3 and ADAM17 at the cell surface is likely a key determinant of ADAM17 activity. Biochemical confirmation of this in brain arteries will require further investigation, although the lack of ADAM17 and TIMP3 antibodies suitable for immunohistochemistry, the tiny amount of material provided by segments of cerebral arteries for biochemical studies, and the lack of in situ or specific assay to assess ADAM17 activity in tissues remain major technical obstacles.

Although many of the molecular details of the mechanism responsible for EGFR-mediated suppression of K~V~ channels in cerebral arterial myocytes remain unsettled, previous studies have shown that activation of EGFR tyrosine kinase activity can suppress K~V~ channel activity through enhanced endocytosis ([@bib28]; [@bib20]). Functional homo- or heteromeric K~V~ channels are formed from four α-subunits, plus additional β-subunits. K~V~1.5, and to a lesser extent K~V~1.2, are the predominant α-subunits in rodent brain arteries ([@bib47]; [@bib46]). Whereas direct tyrosine phosphorylation of the channel has been identified as the mechanism regulating K~V~ 1.2 endocytosis in HEK or neuronal cells ([@bib34]), a role for this mechanism in K~V~1.5 endocytosis has not yet been demonstrated ([@bib20]). Whether other subunits within the K~V~ 1.5 channel complex or a closely associated protein is the target of phosphorylation remains to be tested. On the other hand, K~V~ channel suppression could be mediated by enhanced lysosomal or proteasomal degradation, as recently shown for K~V~ 1.5 in mesenteric arteries ([@bib27]). Future experiments are needed to elucidate mechanisms responsible for the regulation and trafficking of K~V~1 channels in cerebral arterial myocytes.

In summary, our study has uncovered a novel and central role for the ADAM17/HB-EGF/ErbB/K~V~ signaling pathway in the physiological and pathological control of CBF and arterial tone. Our results highlight a heretofore-unrecognized mechanistic link between pathological alterations of the vascular extracellular matrix and K~V~ channel density that underlies cerebrovascular dysfunction in CADASIL. We believe that this novel extracellular matrix-dependent mechanism establishes an important paradigm for cerebrovascular regulation. Importantly, illumination of its dysfunction in cerebral small vessel disease offers multiple points of potential therapeutic intervention that may prove to be more easily druggable than pathological changes in vascular extracellular matrix.

Material and methods {#s4}
====================

Reagents {#s4-1}
--------

Acetylcholine, adenosine, the selective ErbB1/ErbB4 inhibitor tyrphostin AG1478, and the selective ErbB2 inhibitor tyrphostin AG825 ([@bib29]) were purchased from Sigma Aldrich (St. Louis, MO). Heparin was purchased from Merck Millipore (Molsheim, France). The ADAM inhibitors GI254023X (ADAM 10) and GW413333X (ADAM10/ADAM17) ([@bib17]) were synthesized by Iris Biotech (Marktredwitz, Germany). Murine recombinant TIMP1, murine soluble ErbB1, ErbB3 and ErbB4 receptor traps (ErbB1-IgG1 Fc, ErbB3-IgG2 Fc and ErbB4-IgG2 Fc), and control IgG1 Fc and IgG2 Fc fragments, as well as human bioactive ADAM17 were purchased from R&D Systems (Lille, France). Murine recombinant TIMP2 and TIMP3 were purchased from Uscn Life Science (Houston, TX, and murine sHB-EGF was purchased from BioVision (Milpitias, CA). The p21 peptide (H-KKK KKG KGL GKK RDP CLR KYK-OH), which competitively inhibits HB-EGF binding to heparan sulfate proteoglycan ([@bib15]), and a mutated, inactive peptide in which all lysine residues that are important for inhibitory activity are replaced with alanines (p21-mut; H-AAA AAG AGL GAA RDP CLR AYA-OH) were purchased from Eurogenetec (Seraing, Belgium) and resuspended at a concentration of 25 mM in DMSO, following the manufacturer's directions. Paxilline was purchased from A.G. Scientific (San Diego, CA). Apamin and charybdotoxin were purchased from Enzo Life Sciences (Farmingdale, NY). Papain and collagenase type 4 were purchased from Worthington Biochemical Corporation (Lakewood, NJ). All other chemicals were obtained from Sigma Aldrich.

Mice {#s4-2}
----

*Experiments were conducted in* FVB/N mice (Charles River Laboratories, France); transgenic mice overexpressing the R169C mutation of Notch3 (*TgNotch3^R169C^*, line 88), bred on an FVB/N background ([@bib23]); transgenic mice overexpressing human TIMP3 (*TgBAC-TIMP3*), bred on a hybrid background (88% FVB/N/12% C57Bl/6) ([@bib6]); homozygous *Adam17^ex/ex^* mice, which express profoundly reduced ADAM17 protein levels in all tissues; and heterozygous *Adam17^ex/+^*mice and wild-type littermates ([@bib9]), maintained on a C57BL/6-SV129 hybrid background. Genotyping analyses were performed by polymerase chain reaction (PCR) using the following primer pairs: *TgNotch3*, 5'-TCA ACG CCT TCT CGT TCT TC-3' (forward) and 5'-AAT ACC GTC GTG CTT TCG AG-3' (reverse); *TgBAC-TIMP3*, 5'-CCA GGA GAC AGC AAG TAG CC-3' (forward) and 5'-GCT GCT GTT TAG GGA TCT GC-3' (reverse); *Adam17 *mutant and wild-type allele, 5'- TAT GTG ATA GGT GTA ATG -3' (forward) and 5' CTT ATT ATT CTC GTG GTC ACC -3'(reverse).

Mice were bred and housed in pathogen-free animal facilities and fed a standard diet ad libitum with free access to water. All experiments described in this study were conducted in full accordance with the guidelines of our local Institutional Animal Care and Use Committee (Lariboisière-Villemin), with every effort being made to minimize the number of animals used. All mice were male, aged 2 months, except for *TgNotch3^R169C^, TgBAC-TIMP3* and non-transgenic littermate mice, which were 6 months old. We report this study in compliance with the ARRIVE guidelines.

Western blotting {#s4-3}
----------------

Protein extracts were prepared from cerebral pial arteries and immunoblotted using rabbit polyclonal anti-ADAM17 (18.2) (1:2000) ([@bib9]) and anti-smooth muscle α-actin (Clone 1A4, Dako; Les Ulis, France) antibodies, as previously described ([@bib33]). Densitometric quantification of band intensity was performed using ImageJ (version 10.2, NIH).

In vivo analysis of cerebrovascular reactivity {#s4-4}
----------------------------------------------

### Surgical procedure {#s4-4-1}

Mice were anesthetized with isoflurane (maintenance, 2%), tracheally intubated, and artificially ventilated with an oxygen-nitrogen mixture using a ventilator (Sar-830/P; CWE Inc.). The femoral artery was cannulated for recording mean arterial pressure and collecting blood samples. A small craniotomy (2 × 2 mm) was performed to expose the whisker-barrel area of the somatosensory cortex, the dura was removed, and the site was superfused with Ringer's solution (37°C, pH 7.3--7.4). After surgery, isoflurane was gradually discontinued and anesthesia was maintained with urethane (750 mg kg^−1^) and chloralose (50 mg kg^−1^). Rectal temperature was maintained at 37°C, and arterial blood gases were measured. The level of anesthesia was monitored by testing corneal reflexes and motor responses to tail pinch. To minimize confounding effects of anesthesia on vascular reactivity, we kept the time interval between the administration of urethane-chloralose and the testing of CBF responses consistent among the different groups of mice studied. Arterial blood pressure, blood gases, and rectal temperature were monitored and controlled.

### CBF monitoring {#s4-4-2}

Relative CBF was continuously monitored at the site of the cranial window using a laser-Doppler probe (Moor Instruments; Axminster, UK) positioned stereotaxically 0.5 to 1 mm from the cortical surface. CBF values were expressed as percent increase relative to the resting level \[(CBF~stimulus~--CBF~resting~)/CBF~resting~\]. Zero values for CBF were obtained after the heart was stopped by an overdose of isoflurane at the end of the experiment ([@bib5]).

CBF recordings were started after arterial pressure and blood gases had reached a steady state, as previously described ([@bib5]). All pharmacological agents and drugs studied were dissolved in a modified Ringer's solution ([@bib14]). The increase in CBF produced by somatosensory activation was assessed by stimulating the whiskers contralateral to the cranial window by side-to-side deflection for 60 s. The endothelium-dependent vasodilator acetylcholine (10 µmol/L; Sigma-Aldrich) was topically superfused for 5 min, and the resulting changes in CBF were monitored. CBF responses to the smooth muscle-dependent relaxant adenosine (400 µM; Sigma-Aldrich) were also examined.

### Pharmacology {#s4-4-3}

The effects of drugs on cerebrovascular reactivity were examined by testing CBF responses to whisker stimulation and adenosine before superfusion, during superfusion of the cranial window with Ringers' solution containing the appropriate vehicle (first step), and after superfusion with Ringers' solution containing the drug for 30 to 90 min (second step) ([Figure 1A](#fig1){ref-type="fig"}). In some studies, a third step was added to test the joint effect of two compounds. Drug concentrations were based on prior reports ([@bib42]), initial experiments, and a report showing that 100- to 1000-fold higher amounts of drugs are required to achieve effective concentrations in the brain in vivo ([@bib49]). Chemical inhibitors were used at concentrations ranging from 0.1 to 20 µM, recombinant proteins were used at concentrations ranging from 8 to 70 nM, and synthetic peptides were used at 12 µM.

### Assessment of brain penetration of recombinant protein topically applied over the cranial window {#s4-4-4}

Surgical procedures were performed as described above. Ringers' solution containing fluorescein isothiocyanate-labeled serum albumin (FITC-BSA) was topically superfused over the somatosensory cortex for 30 min. The mouse was then transcardially perfused with 20 ml of phosphate-buffered saline (PBS) and 30 ml of 4% paraformaldehyde, and, after sacrificing the animal, the brain was removed and post-fixed in 4% paraformaldehyde overnight. The brain was sectioned in 50-µm-thick coronal slices through the perfusion site using a vibratome, washed in PBS, immunostained with Alexa 594-conjugated anti-smooth muscle α-actin (1:500, clone 1A4; Abcam, Paris, France) and mounted on a glass slide in a drop of Dako fluorescence mounting medium (Dako; Les Ulis, France). Stained sections were imaged with a Nikon Eclipse 80i microscope (Nikon; Champigny sur Marne, France); images were captured with an Andor Neo sCMOS camera and NIS Elements BR v 4.0 software (Nikon) using identical settings across compared groups.

Local field potential recordings {#s4-5}
--------------------------------

Mice were anesthetized and surgically prepared as described above. Field potentials were recorded using a stainless steel bipolar electrode placed in the somatosensory cortex contralateral to the activated whiskers (3 mm lateral and 1.5 mm caudal to bregma; depth, 0.5 mm). The somatosensory cortex was activated by two needle electrodes (21 gauge) subdermally inserted in the whisker pad. Each stimulation trial lasted for 1 min (0.65 mA; 0.5 Hz; pulse duration, 1 ms) and the interval between two trials was 10 min. Eight consecutive stimulation trials were performed on each mouse. The first four cycles were carried out in presence of vehicle, and the subsequent four trials were performed in the presence of recombinant TIMP3 (40 nM); analyses were performed on the average of four trials. Data were obtained and recorded using the MP36R System (Biopac System, CA) and analyzed off-line using AcqKnowledge Software (Biopac System, CA).

Pharmacology on pressurized brain arteries and parenchymal arterioles {#s4-6}
---------------------------------------------------------------------

After overdosing with CO~2~, mice were decapitated and their brains were harvested. Arterial segments of the posterior cerebral artery and precapillary segments of parenchymal arterioles that arise from the middle cerebral artery M1 region and perfuse the neocortex were dissected, cannulated on two glass micropipettes in an organ chamber containing physiological salt solution (PSS) maintained at 37°C (pH 7.4), and pressurized using an arteriograph system (Living Systems Instrumentation, Inc., St. Albans, VT) as previously described ([@bib23]). Once prepared, arteries were allowed to stabilize for at least 60 min at a pressure of 60 mmHg until the development of basal tone. Pressure was then switched to 20 mmHg and compounds were added to the chamber for 20 to 60 min before increasing the intraluminal pressure to 40, 60, 80 and 100 mm Hg using a pressure-servo control pump. Vessel internal diameter was continuously recorded using a CCD camera and edge-detection software (Biopac MP150; Biopac Systems Inc., CA or AcqKnowledge Software; IonOptix, Milton, MA). Diameters measured in PSS were considered active diameters. At the conclusion of each experiment, maximal dilation was obtained in nominally Ca^2+^-free PSS containing EGTA (2--5 mM; Sigma). Artery diameters are given in micrometers. Myogenic tone was expressed as the percentage of passive diameter (\[passive diameter -- active diameter\]/passive diameter × 100).

Compound concentrations were based on initial experiments of cerebrovascular reactivity and used at approximately one fifth of the concentration used in vivo.

Arterial myocyte isolation and electrophysiology {#s4-7}
------------------------------------------------

Anterior, middle, and posterior cerebral arteries and arterioles were cleaned of connective tissue and placed in cell-isolation solution. Single smooth muscle cells were isolated from cerebral arteries by enzymatic digestion in papain (0.5 mg/mL) and dithioerythritol (1 mg/mL) for 12 min, followed by a second digestion in collagenase type 4 (1 mg/mL) without Ca^2+^ for 10 min. Digested tissue was washed out and gently triturated with a fire-polished glass pipette. The single-cell suspension of myocytes was refrigerated until use (typically 4--6 hr). Outward K^+^ currents were recorded from single cells in the presence of 1 µM paxilline (to block BK currents) at room temperature using the perforated-cell configuration of the patch-clamp technique. Recording electrodes with resistances of 2--4 MΩ were pulled from borosilicate glass and backfilled with a pipette solution of appropriate composition. Currents were recorded from cells on an Axopatch 200B amplifier, filtered at 2 kHz using a low-pass Bessel filter, and digitized at 10 kHz (Digidata 1322A; Molecular Devices). pCLAMP-9 software (Molecular Devices) was used for data recording and analysis. The composition of cell isolation solution was 60 mM NaCl, 85 mM Na-glutamate, 3 mM KCl, 2 mM MgCl~2~, 10 mM HEPES, 10 mM glucose, 7 mM mannitol, pH 7.4. For patch-clamp experiments, the bath solution composition was 137 mM NaCl, 3 mM KCl, 0.1 mM CaCl~2~, 4 mM glucose, 10 mM HEPES (pH 7.3), and contained paxilline (1 µM); the pipette solution was 10 mM NaCl, 30 mM KCl, 110 mM K-aspartate, 1 mM MgCl~2~, 10 mM HEPES (pH 7.2), and contained 250 µg/mL amphotericin B. Families of outward K~V~ currents were elicited by series of 10-mV depolarizing steps from −70 mV to +60 mV, from a holding potential of −80 mV ([Figure 7a](#fig7){ref-type="fig"}). Current density was calculated by dividing membrane current amplitude at the end of the pulse by cell capacitance.

The relationship between myocyte membrane voltage and the amplitudes of tail currents (*I*) was fit to the Boltzmann equation,$$I = \frac{I_{max}}{1 + e^{{(V_{0.5} + V)}/k}}$$

where *I~max~* is the measured peak tail current, which allows determination of the half-maximal activation potential (*V~0.5~*) and slope (*k*).

### Estimation of the number of channels {#s4-7-1}

In symmetrical, high extracellular K^+^ (\[K^+^\]~o~) and intracellular K^+^ (\[K^+^\]~i~) solutions, the Goldman-Hodgkin-Katz flux equation ([@bib16]) for K^+^ predicts a linear relationship between channel current amplitude, *I,* and membrane potential:$$i = P_{K} \times \frac{EF^{2}}{RT} \times \frac{\left\lbrack K^{+} \right\rbrack_{o} - \left\lbrack K^{+} \right\rbrack_{i}.\exp\left( EF/\left( RT \right) \right)}{1 - \exp\left( EF/\left( RT \right) \right)}.$$

With \[*K*^+^\]~o~ = \[*K*^+^\]*~i~* the equation becomes$$i = P_{K} \times EF^{2}\left\lbrack K^{+} \right\rbrack/\left( RT \right),$$

where *P*~K~ is the permeability to K^+^ of a single channel (in cm/s); *E* is the membrane potential (*V); F, R* and *T* have their usual meanings; and the K^+^ concentration is given in mol/mL. Since K^+^ single-channel conductance is defined as $\gamma = i/E$, permeability can be defined as$$P_{K} = \gamma/\left\lbrack K^{+} \right\rbrack \times \left( RT/F^{2} \right).$$

Using a single-channel conductance of 15 pS recorded in inside-out patches with symmetrical \[K^+^\] = 140 mM ([@bib1]), we calculated *P*~K~ = 2.83 × 10^--14^ cm/s at 23°C. The single-channel current amplitude, *i*, was then estimated using *P*~K~ and the Goldman-Hodgkin-Katz flux equation at a given voltage (−40 mV) with \[K^+^\]~o~ = 3 mM and \[K^+^\]~i~ = 140 mM. Finally, the number of channels (*N*) was determined using the macroscopic current amplitude (*I*) equation, *I = iNP*~o~, with *P*~o~ = 0.014 at −40 mV ([@bib1]).

Statistical analysis {#s4-8}
--------------------

Data are expressed as means ± SEM. Sample size needed for CBF and myogenic tone analysis as well as for electrophysiology experiments was determined based on our prior works ([@bib12]), ([@bib6]); n values indicate the number of biological replicates. CBF responses were analyzed by one-way analysis of variance (ANOVA) or repeated-measure ANOVA followed by Bonferroni or Tukey post-hoc tests. Evoked potential fields were analyzed using unpaired Student's t-test. Myogenic tone and current densities were analyzed by two-way repeated-measure ANOVA followed by Bonferroni post-hoc tests. All statistics were performed using Graph Pad Prism. Differences with p-values \< 0.05 were considered statistically significant. The significance level was set at p\<0.05.
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In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your article \"Mechanistic insights into a TIMP3-sensitive pathway constitutively engaged in the regulation of cerebral hemodynamics\" for consideration by *eLife*. Your article has been favorably evaluated by a Senior editor and three reviewers, including John P Adelman (Reviewer \#2) Scott Earley (Reviewer \#3) and David E Clapham (Reviewer \#1), who is a member of our Board of Reviewing Editors.

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Summary:

The manuscript from Joutel and colleagues reports results that examine the mechanisms by which TIMP3 regulates cerebral arterial tone and CBF responses. Previous work had shown that TIMP3 abnormally accumulates in the extracellular matrix of brain vessels of patients and *TgNotch3^R169C^* mice with CADASIL, a monogenic form of small vessel disease. Genetic overexpression of TIMP3 recapitulates both CBF and myogenic response deficits of the CADASIL model, while genetic reduction of TIMP3 restores normal function. Also, they had previously shown that downregulation of plasma membrane K~v~ channels restored normal responses to pressure. Here, they demonstrate that TIMP3 mediates cerebrovascular function through ADAM17/HB-EGF/EGFR (ErbB1/ErbB4) signaling pathway. In CADASIL, accumulation of TIMP3 leads to the inhibition of ADAM17, consequently, prevents sHB-EGF from being cleaved and affects the subsequent ErbB1/ErbB4 activity. Through a mechanism yet to be determined, this apparently decreases K~v~ 1 channel endocytosis. The enhanced K~v~ 1 channel activity due to increased current density limits the myogenic tone and evoked CBF responses.

This is a very well written manuscript, the data are clearly presented and the results are significant.

Revisions to address:

1\) Application of sADAM17 (16 nM) did not affect responses in wt. This suggests that endogenous levels of ADAM17 are saturated. Was a higher concentration tested? Also, what was the effect of exogenous application of sADAM17 on the stronger hypomorph, *ex/ex*? This would be interesting as it would determine whether the signaling pathway remains intact even when ADAM17 is largely abolished. Indeed, even in the genetic model of TIMP3 over-expression, ADAM17 application improved CBF responses.

2\) Throughout the manuscript, using the in vivo model of direct cortical application, the responsiveness to the various treatments and genetic models are presented as relative, percent changes. Since the system seems to operate at maximum in the basal condition, it would be interesting to know whether there are significant differences in the absolute sense. For example, is resting flow the same for the various genetic models? Does application of ADAM17 normalize CBF in the hypomorph to the same absolute value as wt?

3\) Application of ADAM17 to the hypomorph did not affect the relative change in resting flow, but increased it in the N3^R169C^ model. If the effect of both of these models is to reduce the effective ADAM17 activity, why are the responses on resting flow different?

4\) The main conclusion of this manuscript is that TIMP3 blunts the ADAM17/HB-EGF/ErbB/K~v~ pathway to disrupt neurovascular coupling (NVC) by diminishing myogenic constriction. The authors posit that because arteries and arterioles are already in a dilated state, intrinsic NVC coupling mechanisms cannot further increase CBF. If this is the case, why are increases in CBF due to loss of myogenic tone not seen when exogenous TIMP3 is acutely applied (i.e., [Figure 1](#fig1){ref-type="fig"})?

5\) The authors show that administration of sADAM17 restores NVC in *ADAM17^ex/wt^*mice ([Figure 2](#fig2){ref-type="fig"}). It would be useful to show that sADAM17 also restores impaired myogenic reactivity in isolated cerebral arteries from these mice. These new experiments would provide a direct mechanistic link between restoration of myogenic tone and repair of NVC.

6\) Ex vivo experiments examining myogenic reactivity used cerebral pial arteries, but NVC is primarily regulated by parenchymal (penetrating) arterioles. Prior work from some of the co-authors and other labs indicate that the signaling pathways responsible for vascular contractility differ between smooth muscle cells from pial versus parenchymal arterioles. Additional experiments using isolated cerebral parenchymal arterioles would be helpful to resolve this issue.

7\) Patch-clamp experiments -- The effects of exogenous TIMP3 are quite modest and in all experiments shown here, K~v~ current densities differ only at very positive membrane potentials. The prior study from this research group (PMID:25646445) shows increases in current density between *TgNotch3^R169C^* and wild-type mice at membrane potentials that are physiologically relevant for smooth muscle cells (i.e., -30 mV). If the authors\' proposed mechanism is correct, a larger influence of TIMP3 at these membrane potentials would be expected. These findings call into question the authors\' contention that increases in K~v~ channel surface expression accounts for loss of myogenic contractility. Perhaps a more through characterization of electrophysiological properties is needed that would encompass other K^+^ channels (BK) as well as depolarizing influences (TMEM16A, TRPC6, TRPM4). At a minimum, the authors should at least discuss the limitations of the data that are presented.
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Author response

*Revisions to address:*

*1) Application of sADAM17 (16 nM) did not affect responses in wt. This suggests that endogenous levels of ADAM17 are saturated. Was a higher concentration tested? Also, what was the effect of exogenous application of sADAM17 on the stronger hypomorph, ex/ex? This would be interesting as it would determine whether the signaling pathway remains intact even when ADAM17 is largely abolished. Indeed, even in the genetic model of TIMP3 over-expression, ADAM17 application improved CBF responses.*

We did not test a higher concentration of sADAM17 in wildtype mice. Interestingly, results of a recent study support the idea that endogenous levels of ADAM17 are indeed saturated. Yoda and colleagues recently showed that ADAM17 transgenic mice, which overexpress ADAM17 mRNA and protein, exhibit no overt defects and no enhanced shedding activity of ADAM17, both in vitro and in vivo (Yoda M et al., PLoS One 2013;8(1):e54412. PMID: 23342154). We thank the reviewers for this insightful comment and this point has been added in the revision (Discussion, fourth paragraph).

We acknowledge that it would have been desirable to perform more experiments in the *ADAM17^ex/wt^*and ADAM17^ex/ex^ mice. However, because we had a limited access to these mice -- we did not set up the colony but imported the mice into the Institute where the CBF experiments have been conducted -- and because only one compound can be tested in a given mouse, we prioritized the use of *ADAM17^ex/wt^*mice to test the effect of sADAM17, as shown on [Figure 2](#fig2){ref-type="fig"}, and the use of ADAM17^ex/ex^ mice to test the effect of sHB-EGF. Results of this later experiment, now included in the revision, showed that exogenous application of sHB-EGF significantly improved the CBF responses in the ADAM17 ^ex/ex^ mice, suggesting that the signaling pathway remains intact in these mice (Results, subsection "HB-EGF and EGFR operate downstream of ADAM17 to regulate CBF responses", last paragraph; [Figure 4---figure supplement 2](#fig4s2){ref-type="fig"}).

*2) Throughout the manuscript, using the in vivo model of direct cortical application, the responsiveness to the various treatments and genetic models are presented as relative, percent changes. Since the system seems to operate at maximum in the basal condition, it would be interesting to know whether there are significant differences in the absolute sense. For example, is resting flow the same for the various genetic models? Does application of ADAM17 normalize CBF in the hypomorph to the same absolute value as wt?*

We thank the reviewers for raising this important point. Although laser Doppler flow (LDF) derived measurements provide an accurate assessment of relative CBF changes, it is usually considered that LDF is less accurate for obtaining absolute flow measurements and therefore we did not incorporate these values in the original submission. Having said that, we had an excellent day-to-day reproducibility of CBF measurements and we fully agree that absolute flow measurements in the genetic models used in the current study are worth considering. Interestingly, we found that in the *ADAM17^ex/wt^*mice, resting flow was not significantly decreased and unchanged upon topical application of sADAM17. In contrast, in TgBAC-TIMP3 and *TgNotch3^R169C^* mice, resting CBF was significantly reduced, and significantly improved upon application of sADAM17, with values close to values observed in WT mice. Therefore, it appears that application of sADAM17 in these genetic models normalize resting and evoked CBF responses towards the same absolute values of WT mice.

Accordingly, we now provide in the revision absolute values of resting flows for the genetic models (Results, subsections "ADAM17 is required for TIMP3-induced attenuation of CBF responses" and "Exogenous sADAM17 and exogenous sHB-EGF rescue CBF and myogenic-response deficits in the *TgNotch3^R169C^* CADASIL model"; [Figure 2---figure supplement 2](#fig2s2){ref-type="fig"}; revised [Figure 6---figure supplement 1](#fig6s1){ref-type="fig"}; revised [Figure 2---source data 3](#SD6-data){ref-type="supplementary-material"} and [Figure 6---source data 2](#SD16-data){ref-type="supplementary-material"}).

*3) Application of ADAM17 to the hypomorph did not affect the relative change in resting flow, but increased it in the* N3^R169C^ *model. If the effect of both of these models is to reduce the effective ADAM17 activity, why are the responses on resting flow different?*

We thank the reviewers for stressing this point. The responses on resting flow appear different in the *ADAM17^ex/wt^*and *TgNotch3^R169C^* mice if we consider the relative changes. However, results appear more consistent if we consider the absolute values. Indeed, as mentioned above, resting flow is unchanged in *ADAM17^ex/wt^*and unaffected by topical application of sDAM17. In contrast, resting flow, which is decreased in the *TgNotch3^R169C^* mice, is improved by exogenous sADAM17 towards wildtype values, suggesting that sADAM17 acts to normalize CBF responses to values observed in WT mice. We have clarified this point in the revision (Results subsections "ADAM17 is required for TIMP3-induced attenuation of CBF responses" and "Exogenous sADAM17 and exogenous sHB-EGF rescue CBF and myogenic-response deficits in the *TgNotch3^R169C^* CADASIL model"; [Figure 2---figure supplement 2](#fig2s2){ref-type="fig"}; revised [Figure 6---figure supplement 1](#fig6s1){ref-type="fig"}; revised [Figure 2---source data 3](#SD6-data){ref-type="supplementary-material"} and [Figure 6---source data 2](#SD16-data){ref-type="supplementary-material"}).

*4) The main conclusion of this manuscript is that TIMP3 blunts the ADAM17/HB-EGF/ErbB/*K~v~ *pathway to disrupt neurovascular coupling (NVC) by diminishing myogenic constriction. The authors posit that because arteries and arterioles are already in a dilated state, intrinsic NVC coupling mechanisms cannot further increase CBF. If this is the case, why are increases in CBF due to loss of myogenic tone not seen when exogenous TIMP3 is acutely applied (i.e., [Figure 1](#fig1){ref-type="fig"})?*

We fully agree that a transient reduction in myogenic tone was theoretically expected to increase resting CBF, and vice versa. Although we proposed several explanations in the initial version of our manuscript, we acknowledge that this important issue deserves further discussion. Accordingly, we have added the following paragraph in the Discussion: "However, although myogenic tone and myogenic responses are known to contribute to the regulation of resting CBF, their relative importance are hard to quantify and poorly understood; their contribution may also change depending on conditions or disease states and other mechanisms---metabolic, neural, endothelial---also influence or contribute to resting CBF (Cipolla, 2009). It is also possible that overall resting CBF does not change despite seeing a change in myogenic tone in one portion of the vasculature because of compensatory adjustments in vessels downstream. Simultaneous in vivo recordings of local blood flow and vessel diameter may be of interest to address this possibility".

*5) The authors show that administration of sADAM17 restores NVC in ADAM17^ex/wt^ mice ([Figure 2](#fig2){ref-type="fig"}). It would be useful to show that sADAM17 also restores impaired myogenic reactivity in isolated cerebral arteries from these mice. These new experiments would provide a direct mechanistic link between restoration of myogenic tone and repair of NVC.*

As suggested by the reviewers, these experiments have been carried out. Actually, we found that sADAM17 also restores myogenic tone in *ADAM17^ex/wt^*mice. These data have been added in the revision (Results, subsection "The ADAM17/HB-EGF/(ErbB1/ErbB4) signaling module regulates pressure-induced myogenic tone in brain arteries"; [Figure 5---figure supplement 2](#fig5s2){ref-type="fig"}).

*6) Ex vivo experiments examining myogenic reactivity used cerebral pial arteries, but NVC is primarily regulated by parenchymal (penetrating) arterioles. Prior work from some of the co-authors and other labs indicate that the signaling pathways responsible for vascular contractility differ between smooth muscle cells from pial versus parenchymal arterioles. Additional experiments using isolated cerebral parenchymal arterioles would be helpful to resolve this issue.*

We thank the Reviewers for this valuable comment. First, we would like to point out that, in *TgNotch3^R169C^* mice, we previously established that myogenic responses are similarly impaired in parenchymal arterioles and pial arteries (Dabertrand et al., Proc. Natl. Acad. Sci. 2015;112(7):E796--805), suggesting that the pathway altered by the CADASIL mutation is the same in the pial arteries and intraparenchymal arterioles. Second, as suggested, a new set of experiments has been carried out on parenchymal arterioles (PAs). We compared changes in the diameter of PAs in response to increasing intraluminal pressure. We observed that pre-incubation with TIMP3 blunted the myogenic response compared to pre-incubation with vehicle, whereas recombinant TIMP2 (10 nM) had no effect, suggesting that the TIMP3 sensitive pathway similarly operates in both pial and intraparenchymal arterioles. These data have been included in the revision (Results, subsection "The ADAM17/HB-EGF/(ErbB1/ErbB4) signaling module regulates pressure-induced myogenic tone in brain arteries"; [Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}).

In addition, measurements of pressurized parenchymal arterioles are significantly more challenging than those of pial arteries, with a lower success rate (i.e. more time, money and most importantly animals sacrificed). Therefore, given the extensive number of demanding experiments in the current study and the lack of difference in myogenic impairment of parenchymal arterioles and pial arteries in response to TIMP3 as well as in CADASIL mice, we did not repeat all the pharmacological experiments, shown in the original submission, on the parenchymal arterioles.

*7) Patch-clamp experiments -- The effects of exogenous TIMP3 are quite modest and in all experiments shown here,* K~v~ *current densities differ only at very positive membrane potentials. The prior study from this research group (PMID:25646445) shows increases in current density between TgNotch3^R169C^ and wild-type mice at membrane potentials that are physiologically relevant for smooth muscle cells (i.e., -30 mV). If the authors\' proposed mechanism is correct, a larger influence of TIMP3 at these membrane potentials would be expected. These findings call into question the authors\' contention that increases in* K~v~ *channel surface expression accounts for loss of myogenic contractility. Perhaps a more through characterization of electrophysiological properties is needed that would encompass other K^+^ channels (BK) as well as depolarizing influences (TMEM16A, TRPC6, TRPM4). At a minimum, the authors should at least discuss the limitations of the data that are presented.*

Exogenous TIMP3 increased current density by 21% at positive voltages (+ 40 mV) compared to 72% increase in myocytes from CADASIL cerebral arteries. A 21% increase in current due to an elevation of channel number would be physiological meaningful, but would not be detectable at negative voltages with our experimental approach. Our results are consistent with the idea that the mechanisms to upregulate channel number are less robust than endocytosis of K~v~ channels in isolated myocytes at room temperature. Furthermore, channel trafficking at room temperature (patch clamp analysis on cerebral arterial myocytes) is likely to be slower than at 37°C (intact pressurized arteries and in vivo).

In a previous study, we found that inhibition of BK channels had no effect on pressure-induced constrictions in WT and in CADASIL (Hannah et al., J. Cereb. Blood Flow Metab. 2011; Dabertrand et al., Circ. Res. 2012; Dabertrand et al., Proc. Natl. Acad. Sci.2015). Reduction of K~v~ channel activity by 4-AP, HB-EGF, and genetically (TIMP3^+/-^) in CADASIL to WT levels completely restored myogenic tone and in vivo CBF responses, suggesting that this mechanism was sufficient.

Nonetheless, we cannot absolutely exclude possible effects on pressure-induced hyperpolarizing and depolarizing influences on membrane potential. Therefore we have discussed this in the revision (Discussion).
